What is Quantitative Digital Pathology?

Why would human tissues be used by pharmaceutical and biotech companies as part of their pre-clinical research? Where do they get the tissue from? How do the logistics work? What is key benefits and limitations of using this type of research? This and many more questions will be addressed by my guest David Bunton, CEO of Reprocell Europe, who in line with the theme of this podcast, lives and works in Scotland. 

Welcome to episode 2 of the "What in the Life Sciences?" Podcast! I want to two things with this podcast: A) To explain some of the specific vocabulary in Life Sciences to our listeners. Today we will focus on "Lead Identification". B) To introduce Scottish Life Science firms to a wider audience, especially a Switzerland based one. I am your host, Roland Linder of Scottish Development International (SDI) speaking with Phil Jones, the Chief Science Officer of BioAscent, a Scotland based integrated drug discovery firm.  Enjoy!

This is the very first episode of the "What in the Life Sciences?" Podcast!  I want to two things with this podcast: A) To explain some of the specific vocabulary in Life Sciences, starting with: Quantitative Digital Pathology B) To introduce Scottish Life Science firms to a wider audience, especially a Switzerland based one.  I am your host, Roland Linder of Scottish Development International (SDI) speaking with John Waller, COO of OracleBio. Enjoy!